查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2138143

基因測序和 CRISPR 基因編輯市場預測至 2034 年——按產品和服務、技術、應用、最終用戶和地區分類的全球分析

Genomics Sequencing & CRISPR Gene Editing Market Forecasts to 2034 - Global Analysis By Product & Service, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球基因測序和 CRISPR 基因編輯市場預計將在 2026 年達到 123 億美元，並在預測期內以 16.0% 的複合年成長率成長，到 2034 年達到 403 億美元。

基因測序和CRISPR基因編輯技術將高通量基因定序與標靶基因編輯技術結合，從而能夠更精確地分析和修飾DNA。基因測序有助於闡明突變、遺傳變異和分子特徵，而CRISPR系統則允許研究人員對基因組進行特定的修飾。這種綜合方法有助於醫學研究、治療開發、診斷、農業應用和個人化醫療。科技的不斷進步加深了我們對基因組的理解，拓展了研究能力，並使我們能夠以更精準的方式應對遺傳和生物學挑戰。

根據美國國家人類基因組研究所 (NHGRI) 的數據，創建高品質的人類全基因組序列草圖的成本從 2015 年年中的 4000 多美元下降到 2015 年底的不到 1500 美元，這表明定序的經濟性和技術都得到了顯著改善。

精準醫療的需求日益成長

精準醫療的日益普及正推動基因測序和CRISPR基因編輯市場的擴張。定序技術能夠提供關於基因變異的詳細信息，幫助研究人員和醫療專業人員了解疾病機制，並開發更個人化的診斷和治療方法。同時，CRISPR技術透過實現對特定基因的標靶研究和修飾，增強了研究能力。隨著對個人化醫療的日益重視，製藥公司、生技公司、醫院和研究機構都在積極投資基因測序、基因編輯平台、分析軟體以及相關的實驗室技術。

定序和基因編輯技術高成本

基因測序和CRISPR基因編輯技術所需的大量投資可能會限制其應用。機構可能需要在定序設備、CRISPR平台、專用試劑、運算基礎設施、實驗室設施和技術專長方面投入大量資金。系統維​​護、基因組資料管理、檢驗和人員培訓等持續成本會進一步增加支出。因此，小規模實驗室、新興生技公司和資源有限的醫療機構在採用這些技術時可能會面臨困難。這種成本壓力會阻礙這些技術的廣泛應用，尤其是在先進基因組研究和基因編輯基礎設施的資金仍然有限的情況下。

個人化醫療和精準醫療的擴展

個人化醫療的日益普及為基因測序和CRISPR基因編輯市場帶來了巨大的成長機會。基因測序能夠對個體的DNA圖譜進行全面分析，有助於識別與疾病相關的基因變異，並促進精準醫療策略的改進。 CRISPR技術透過加速針對特定基因和潛在治療方法的研究，進一步拓展了這些機會。對個人化診斷、標靶治療和基因生物標記日益成長的需求，正推動醫院、生物技術公司、製藥公司和研究機構擴大定定序和基因編輯解決方案的應用。

資料隱私與網路安全風險

網路安全問題以及對基因資料保護的擔憂為基因測序和CRISPR基因編輯市場帶來了重大挑戰。定序活動會產生大量敏感的基因組訊息，這些訊息必須得到謹慎的管理和保護。資料外洩、濫用和網路攻擊等潛在風險可能會損害公眾信任，並引發監管問題。政府和監管機構可能會實施更嚴格的資料保護要求，從而增加營運成本和合規相關費用。這些挑戰可能會減緩基因組和基因編輯技術的應用速度，並影響相關投資。

新型冠狀病毒（COVID-19）的影響：

新冠疫情透過增加對病原體基因組分析、變異追蹤和基因研究的需求，對基因測序和CRISPR基因編輯市場產生了影響。基因測序對於監測SARS-CoV-2的變異至關重要，而CRISPR技術則因其在診斷和實驗室應用方面的潛在價值而備受關注。然而，由於監管、供應鏈中斷、實驗室工作停滯和研究專案延遲等原因，出現了一些暫時的挑戰。隨後，疫情刺激了對基因組監測系統、定序能力、計算分析和分子技術的投資增加，加速了基因組研究工具的更廣泛應用。

在預測期內，「設備和排序器」細分市場預計將佔據最大的市場佔有率。

預計在預測期內，儀器和定序領域將佔據最大的市場佔有率，因為它在基因測序和CRISPR相關研究活動中發揮著至關重要的作用。定序平台為DNA分析、基因變異檢測、生物機制研究、基因編輯工作流程提供支援等功能。其應用範圍涵蓋生物技術公司、製藥研究機構、臨床檢查室、大學和醫療機構。儀器自動化、分析性能、定序能力以及與實驗室工作流程整合方面的持續進步，進一步提升了這些平台的重要性，並鞏固了它們在基因組學和基因編輯生態系統中的核心地位。

在預測期內，個人化醫療領域預計將呈現最高的複合年成長率。

在預測期內，隨著醫療保健越來越注重個人化治療，個人化醫療領域預計將呈現最高的成長率。定序技術有助於識別基因特徵、疾病相關突變和相關生物標記物，而 CRISPR 技術則能夠對特定基因路徑進行精準研究。基因組資訊在診斷、治療方案製定和標靶治療研發中的日益廣泛的應用，為個人化醫療創造了更多機會。精準醫療和基因組技術的持續進步，正推動著這一領域的快速發展。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其高度發達的基因組基礎設施、成熟的生物技術產業以及先進定序和基因組編輯技術的廣泛應用。政府、研究機構和私人公司的大力投資為基因組醫學、臨床研究和生物技術領域的創新提供了支持。製藥公司、技術提供者、學術機構和專業實驗室的集中也促進了該地區技術的普及應用。研究能力、醫療基礎設施和技術專長的結合進一步鞏固了北美在基因測序和CRISPR基因編輯領域的領先地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率。生物技術能力的提升、基因組研究計畫的推進以及精準醫療措施正在推動該地區的需求成長。中國、日本、印度、韓國、新加坡和澳洲等國家正在增加對定序平台、基因組編輯和生物醫學研究的投資。不斷拓展的研究夥伴關係、基因組技術的普及以及在臨床診斷和治療開發領域更廣泛的應用，都將進一步促進該地區的成長。近期市場評估一致認為，亞太地區是重要的高成長區域。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球基因測序與CRISPR基因編輯市場：依產品與服務分類

  • 樂器和音序器
  • 耗材和試劑
  • 軟體和生物資訊學工具
  • 服務

第6章 全球基因測序與CRISPR基因編輯市場：依技術分類

  • 次世代定序（NGS）
    • 全基因測序
    • 全EXOME定序
    • 高品質定序和定序
  • CRISPR基因編輯平台
    • Cas9
    • Cas12
    • Cas13
    • 基礎編輯
    • 主編

第7章 全球基因測序與CRISPR基因編輯市場：依應用分類

  • 臨床診斷
  • 藥物發現與開發
  • 農業基因組學
  • 個人化醫療
  • 功能基因體學與研究

第8章 全球基因測序與CRISPR基因編輯市場：依最終使用者分類

  • 學術研究機構
  • 製藥和生物技術公司
  • 臨床實驗室和醫院
  • 農業和環境組織

第9章 全球基因測序與CRISPR基因編輯市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第10章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第11章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第12章：公司簡介

  • Illumina
  • Thermo Fisher Scientific
  • Danaher Corporation
  • CRISPR Therapeutics
  • Vertex Pharmaceuticals
  • Intellia Therapeutics
  • Editas Medicine
  • Beam Therapeutics
  • Prime Medicine
  • Caribou Biosciences
  • Merck KGaA
  • Sangamo Therapeutics
  • Metagenomi
  • Mammoth Biosciences
  • Scribe Therapeutics
  • Tessera Therapeutics
  • Pacific Biosciences
  • Oxford Nanopore Technologies
Product Code: SMRC39742

According to Stratistics MRC, the Global Genomics Sequencing & CRISPR Gene Editing Market is accounted for $12.3 billion in 2026 and is expected to reach $40.3 billion by 2034 growing at a CAGR of 16.0% during the forecast period. Genomics Sequencing & CRISPR Gene Editing brings together high-throughput genetic sequencing and targeted gene-editing technologies to analyze and alter DNA with increasing precision. Genomic sequencing helps reveal mutations, genetic variations, and molecular characteristics, whereas CRISPR systems enable researchers to make specific modifications within genomes. The combined approach is contributing to medical research, therapeutic development, diagnostics, agricultural applications, and personalized healthcare. Continued technological progress is strengthening genomic understanding, expanding research capabilities, and enabling more precise approaches to addressing genetic and biological challenges.

According to the National Human Genome Research Institute (NHGRI), the cost of generating a high-quality draft whole human genome sequence fell from just above $4,000 in mid-2015 to below $1,500 by late 2015, demonstrating the substantial improvement in sequencing economics and technology.

Market Dynamics:

Driver:

Rising demand for precision medicine

Increasing adoption of precision medicine is supporting expansion of the Genomics Sequencing & CRISPR Gene Editing Market. Sequencing technologies provide detailed information about genetic variations, helping researchers and healthcare professionals understand disease mechanisms and develop more individualized approaches to diagnosis and treatment. Meanwhile, CRISPR enables targeted study and modification of specific genes, strengthening research capabilities. The increasing focus on personalized healthcare is encouraging pharmaceutical companies, biotechnology firms, hospitals, and research institutions to invest in genomic sequencing, gene-editing platforms, analytical software, and supporting laboratory technologies.

Restraint:

High cost of sequencing and gene-editing technologies

Significant investment requirements can limit adoption of genomics sequencing and CRISPR gene-editing solutions. Organizations may need to spend heavily on sequencing equipment, CRISPR platforms, specialized reagents, computational infrastructure, laboratory facilities, and technical expertise. Ongoing costs for system maintenance, genomic data management, validation, and workforce training can further increase expenses. Smaller laboratories, emerging biotechnology firms, and resource-constrained healthcare organizations may therefore face difficulties implementing these technologies. Such cost pressures can restrict broader utilization, particularly where funding for advanced genomic research and gene-editing infrastructure remains limited.

Opportunity:

Expansion of personalized and precision healthcare

Increasing adoption of personalized healthcare offers considerable growth opportunities for the Genomics Sequencing & CRISPR Gene Editing Market. Genomic sequencing enables comprehensive examination of individual DNA profiles, supporting identification of genetic variations associated with diseases and improving precision-oriented healthcare strategies. CRISPR technology further expands opportunities by facilitating targeted investigation of genes and potential therapeutic approaches. Rising demand for individualized diagnostics, targeted therapies, and genetic biomarkers is encouraging hospitals, biotechnology companies, pharmaceutical organizations, and research institutes to expand their use of sequencing and gene-editing solutions.

Threat:

Data privacy and cybersecurity risks

Cybersecurity issues and concerns over genetic data protection pose significant challenges for the Genomics Sequencing & CRISPR Gene Editing Market. Sequencing activities produce extensive amounts of confidential genomic information that must be carefully managed and protected. Potential risks such as data leaks, unauthorized usage, or cyberattacks can affect public confidence and create regulatory complications. Governments and regulatory agencies may introduce stricter data protection requirements, increasing operational and compliance expenses. Such challenges can limit the pace of adoption and affect investments in genomic and gene-editing technologies.

Covid-19 Impact:

The COVID-19 pandemic affected the Genomics Sequencing & CRISPR Gene Editing Market by creating greater demand for pathogen genome analysis, variant tracking, and genetic research. Genomic sequencing became important for monitoring changes in SARS-CoV-2, while CRISPR technologies gained attention for potential diagnostic and laboratory applications. However, restrictions, disrupted supply chains, laboratory interruptions, and postponed research programs created temporary challenges. The pandemic subsequently encouraged greater investment in genomic surveillance systems, sequencing capacity, computational analysis, and molecular technologies, supporting broader adoption of genomic research tools.

The instruments & sequencers segment is expected to be the largest during the forecast period

The instruments & sequencers segment is expected to account for the largest market share during the forecast period due to its fundamental role in enabling genomic sequencing and CRISPR-related research activities. Sequencing platforms provide essential capabilities for analyzing DNA, detecting genetic variations, studying biological mechanisms, and supporting gene-editing workflows. Their applications extend across biotechnology companies, pharmaceutical research, clinical laboratories, universities, and healthcare settings. Ongoing advances in instrument automation, analytical performance, sequencing capabilities, and integration with laboratory workflows are further increasing the importance of these platforms and reinforcing their central role within the genomics and gene-editing ecosystem.

The personalized medicine segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the personalized medicine segment is predicted to witness the highest growth rate as healthcare increasingly focuses on individualized approaches. Sequencing technologies help identify genetic characteristics, disease-related variants, and relevant biomarkers, while CRISPR enables precise study of specific genetic pathways. The growing use of genomic information for diagnosis, treatment planning, and development of targeted therapies is creating broader opportunities for personalized medicine. Continued progress in precision healthcare and genomic technologies is supporting the segment's rapid expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its well-developed genomics infrastructure, established biotechnology sector, and extensive use of advanced sequencing and genome-editing technologies. Strong investment from government, research organizations, and private companies supports innovation in genomic medicine, clinical research, and biotechnology. A concentration of pharmaceutical companies, technology providers, academic institutions, and specialized laboratories also contributes to regional adoption. This combination of research capabilities, healthcare infrastructure, and technological expertise reinforces North America's prominent position in genomics sequencing and CRISPR gene editing.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Expansion of biotechnology capabilities, genomic research programs, and precision healthcare initiatives is increasing regional demand. Countries including China, Japan, India, South Korea, Singapore, and Australia are strengthening investments in sequencing platforms, genome editing, and biomedical research. Growing research partnerships, greater access to genomic technologies, and wider applications in clinical diagnostics and therapeutic development are further supporting expansion. Recent market assessments consistently identify Asia Pacific as a leading high-growth region.

Key players in the market

Some of the key players in Genomics Sequencing & CRISPR Gene Editing Market include Illumina, Thermo Fisher Scientific, Danaher Corporation, CRISPR Therapeutics, Vertex Pharmaceuticals, Intellia Therapeutics, Editas Medicine, Beam Therapeutics, Prime Medicine, Caribou Biosciences, Merck KGaA, Sangamo Therapeutics, Metagenomi, Mammoth Biosciences, Scribe Therapeutics, Tessera Therapeutics, Pacific Biosciences and Oxford Nanopore Technologies.

Key Developments:

In February 2026, Danaher Corp. agreed to acquire Masimo Corp. for $9.9 billion in a move to strengthen its diagnostics business. Under the terms of the agreement, Danaher will acquire all the outstanding shares of Masimo for $180 per share in cash, representing a 38.3% premium to Masimo's last closing price.

In October 2025, Thermo Fisher Scientific Inc. has agreed to acquire Clario Holdings Inc., a provider of digital endpoint data solutions for clinical trials. The deal includes potential additional earnout and other payments contingent on future performance. Clario's platform integrates clinical trial endpoint data from devices, sites, and patients, enabling pharmaceutical and biotechnology companies to digitally collect, manage, and analyze clinical evidence across all phases of drug development.

Product & Services Covered:

  • Instruments & Sequencers
  • Consumables & Reagents
  • Software & Bioinformatics Tools
  • Services

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • CRISPR Gene Editing Platforms

Applications Covered:

  • Clinical Diagnostics
  • Drug Discovery & Development
  • Agricultural Genomics
  • Personalized Medicine
  • Functional Genomics & Research

End Users Covered:

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Clinical Laboratories & Hospitals
  • Agricultural & Environmental Organizations

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Genomics Sequencing & CRISPR Gene Editing Market, By Product & Service

  • 5.1 Instruments & Sequencers
  • 5.2 Consumables & Reagents
  • 5.3 Software & Bioinformatics Tools
  • 5.4 Services

6 Global Genomics Sequencing & CRISPR Gene Editing Market, By Technology

  • 6.1 Next-Generation Sequencing (NGS)
    • 6.1.1 Whole Genome Sequencing
    • 6.1.2 Whole Exome Sequencing
    • 6.1.3 Targeted Sequencing & Resequencing
  • 6.2 CRISPR Gene Editing Platforms
    • 6.2.1 Cas9
    • 6.2.2 Cas12
    • 6.2.3 Cas13
    • 6.2.4 Base Editing
    • 6.2.5 Prime Editing

7 Global Genomics Sequencing & CRISPR Gene Editing Market, By Application

  • 7.1 Clinical Diagnostics
  • 7.2 Drug Discovery & Development
  • 7.3 Agricultural Genomics
  • 7.4 Personalized Medicine
  • 7.5 Functional Genomics & Research

8 Global Genomics Sequencing & CRISPR Gene Editing Market, By End User

  • 8.1 Academic & Research Institutes
  • 8.2 Pharmaceutical & Biotechnology Companies
  • 8.3 Clinical Laboratories & Hospitals
  • 8.4 Agricultural & Environmental Organizations

9 Global Genomics Sequencing & CRISPR Gene Editing Market, By Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Netherlands
    • 9.2.7 Belgium
    • 9.2.8 Sweden
    • 9.2.9 Switzerland
    • 9.2.10 Poland
    • 9.2.11 Rest of Europe
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 South Korea
    • 9.3.5 Australia
    • 9.3.6 Indonesia
    • 9.3.7 Thailand
    • 9.3.8 Malaysia
    • 9.3.9 Singapore
    • 9.3.10 Vietnam
    • 9.3.11 Rest of Asia Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Colombia
    • 9.4.4 Chile
    • 9.4.5 Peru
    • 9.4.6 Rest of South America
  • 9.5 Rest of the World (RoW)
    • 9.5.1 Middle East
      • 9.5.1.1 Saudi Arabia
      • 9.5.1.2 United Arab Emirates
      • 9.5.1.3 Qatar
      • 9.5.1.4 Israel
      • 9.5.1.5 Rest of Middle East
    • 9.5.2 Africa
      • 9.5.2.1 South Africa
      • 9.5.2.2 Egypt
      • 9.5.2.3 Morocco
      • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

  • 10.1 Industry Value Network and Supply Chain Assessment
  • 10.2 White-Space and Opportunity Mapping
  • 10.3 Product Evolution and Market Life Cycle Analysis
  • 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

  • 11.1 Mergers and Acquisitions
  • 11.2 Partnerships, Alliances, and Joint Ventures
  • 11.3 New Product Launches and Certifications
  • 11.4 Capacity Expansion and Investments
  • 11.5 Other Strategic Initiatives

12 Company Profiles

  • 12.1 Illumina
  • 12.2 Thermo Fisher Scientific
  • 12.3 Danaher Corporation
  • 12.4 CRISPR Therapeutics
  • 12.5 Vertex Pharmaceuticals
  • 12.6 Intellia Therapeutics
  • 12.7 Editas Medicine
  • 12.8 Beam Therapeutics
  • 12.9 Prime Medicine
  • 12.10 Caribou Biosciences
  • 12.11 Merck KGaA
  • 12.12 Sangamo Therapeutics
  • 12.13 Metagenomi
  • 12.14 Mammoth Biosciences
  • 12.15 Scribe Therapeutics
  • 12.16 Tessera Therapeutics
  • 12.17 Pacific Biosciences
  • 12.18 Oxford Nanopore Technologies

List of Tables

  • Table 1 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Product & Service (2023-2034) ($MN)
  • Table 3 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Instruments & Sequencers (2023-2034) ($MN)
  • Table 4 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Consumables & Reagents (2023-2034) ($MN)
  • Table 5 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Software & Bioinformatics Tools (2023-2034) ($MN)
  • Table 6 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Services (2023-2034) ($MN)
  • Table 7 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 8 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 9 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Whole Genome Sequencing (2023-2034) ($MN)
  • Table 10 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Whole Exome Sequencing (2023-2034) ($MN)
  • Table 11 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Targeted Sequencing & Resequencing (2023-2034) ($MN)
  • Table 12 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By CRISPR Gene Editing Platforms (2023-2034) ($MN)
  • Table 13 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Cas9 (2023-2034) ($MN)
  • Table 14 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Cas12 (2023-2034) ($MN)
  • Table 15 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Cas13 (2023-2034) ($MN)
  • Table 16 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Base Editing (2023-2034) ($MN)
  • Table 17 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Prime Editing (2023-2034) ($MN)
  • Table 18 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Application (2023-2034) ($MN)
  • Table 19 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Clinical Diagnostics (2023-2034) ($MN)
  • Table 20 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Drug Discovery & Development (2023-2034) ($MN)
  • Table 21 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Agricultural Genomics (2023-2034) ($MN)
  • Table 22 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Personalized Medicine (2023-2034) ($MN)
  • Table 23 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Functional Genomics & Research (2023-2034) ($MN)
  • Table 24 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By End User (2023-2034) ($MN)
  • Table 25 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 26 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 27 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Clinical Laboratories & Hospitals (2023-2034) ($MN)
  • Table 28 Global Genomics Sequencing & CRISPR Gene Editing Market Outlook, By Agricultural & Environmental Organizations (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.